About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Evolocumab

Company: Amgen
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 16 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

16 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Recruiting NCT NCT03753555

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques

Not yet reported General Hospital of Shenyang Military Region 100 participants Est. completion 2027-11-30 1 site Stand-alone

Cardiovascular disease Other conditions: Atherosclerosis, Cerebral
View official trial listing →
Recruiting NCT NCT04847752

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Tongji Hospital 1000 participants Est. completion 2028-12-31 1 site

Cardiovascular disease Other conditions: Large-Artery Atherosclerosis (Embolus/Thrombosis)
View official trial listing →
Recruiting NCT NCT04968509

Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis

Not yet reported Beijing Anzhen Hospital 160 participants Est. completion 2028-01 1 site Stand-alone

Other conditions: Aortic Stenosis
View official trial listing →
Recruiting NCT NCT05152888

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

Not yet reported Brigham and Women's Hospital 50 participants Est. completion 2027-12-31 1 site Stand-alone

Other conditions: Stable Coronary Disease
View official trial listing →
Recruiting NCT NCT05430828

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Federico II University 5000 participants Est. completion 2030-03-31 27 sites

Other conditions: Hypercholesterolemia
View official trial listing →
Recruiting NCT NCT05641753

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Not yet reported NYU Langone Health 125 participants Est. completion 2027-07-31 4 sites Stand-alone

Other conditions: Type 1 Diabetes
View official trial listing →
Recruiting NCT NCT06496243

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Not yet reported NewAmsterdam Pharma 69 participants Est. completion 2027-02 1 site Stand-alone

Other conditions: Dyslipidemias
View official trial listing →
Recruiting NCT NCT06700720

YN001-004 in Patients With Coronary Atherosclerosis in Australia

Not yet reported Beijing Inno Medicine Co., Ltd. 24 participants Est. completion 2026-06 7 sites Stand-alone

Cardiovascular disease Other conditions: Coronary Atherosclerotic Disease
View official trial listing →
Recruiting NCT NCT06738758

Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)

Yun Dai Chen 6000 participants Est. completion 2027-12-31 1 site

Other conditions: Acute Coronary Syndromes
View official trial listing →
Recruiting NCT NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Novartis Pharmaceuticals 2382 participants Est. completion 2027-09-30 20 sites

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT07143149

Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China

Not yet reported Beijing Tiantan Hospital 4000 participants Est. completion 2028-03-31 1 site

Cardiovascular disease Other conditions: Transient Ischemic Attack (TIA)
View official trial listing →
Recruiting NCT NCT07388420

Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

Not yet reported General Hospital of Shenyang Military Region 40 participants Est. completion 2026-12-31 1 site Stand-alone

Other conditions: Hypertriglyceridemia Induced Acute Pancreatitis
View official trial listing →
Recruiting NCT NCT07540741

Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke

First Affiliated Hospital of Harbin Medical University 1000 participants Est. completion 2027-12-01 1 site

Cardiovascular disease
View official trial listing →
Recruiting NCT NCT07543731

A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

Novartis Pharmaceuticals 5995 participants Est. completion 2026-10-30 1 site

Cardiovascular disease Other conditions: Hypercholesterolemia, Familial
View official trial listing →
Recruiting NCT NCT07612774

CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

Not yet reported West China Hospital 233 participants Est. completion 2029-01-31 1 site Stand-alone

Cardiovascular disease Other conditions: Coronary
View official trial listing →
Recruiting NCT NCT07704918

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

Not yet reported University of Colorado, Denver 40 participants Est. completion 2028-12 1 site Stand-alone

Other conditions: Melanoma
View official trial listing →
Completed NCT NCT01133522

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

Not yet reported Amgen 60 participants Est. completion 2011-09-14 Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01375751

Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Not yet reported Amgen 168 participants Est. completion 2012-05-16 Stand-alone

Other conditions: Hypercholesterolemia, Familial
View official trial listing →
Completed NCT NCT01375764

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

Not yet reported Amgen 160 participants Est. completion 2012-05-08 42 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01375777

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Not yet reported Amgen 411 participants Est. completion 2012-03-02 58 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01380730

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

Not yet reported Amgen 631 participants Est. completion 2012-04-05 100 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01439880

Open Label Study of Long Term Evaluation Against LDL-C Trial

Not yet reported Amgen 1324 participants Est. completion 2018-06-20 187 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT01516879

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Not yet reported Amgen 905 participants Est. completion 2013-10-14 96 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT01588496

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Not yet reported, Not yet reported Amgen 58 participants Est. completion 2014-01-31 21 sites Stand-alone

Other conditions: Homozygous Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT01624142

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Not yet reported, Not yet reported Amgen 300 participants Est. completion 2018-05-11 44 sites Stand-alone

Other conditions: Severe Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT01652703

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

Not yet reported Amgen 310 participants 42 sites Stand-alone

Other conditions: Hypercholesterolemia and High Risk for Cardiovascular Events
View official trial listing →
Completed NCT NCT01763827

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Not yet reported Amgen 615 participants Est. completion 2013-10-29 83 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01763866

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Not yet reported Amgen 2067 participants Est. completion 2013-12-04 244 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01763905

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Not yet reported Amgen 307 participants Est. completion 2013-11-19 58 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01763918

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Not yet reported Amgen 331 participants Est. completion 2013-12-19 39 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT01764633

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Not yet reported Amgen 27564 participants Est. completion 2016-11-11 1284 sites Stand-alone

Other conditions: Dyslipidemia
View official trial listing →
Completed NCT NCT01813422

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Not yet reported Amgen 970 participants Est. completion 2016-07-29 226 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT01849497

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Not yet reported Amgen 149 participants 26 sites Stand-alone

Other conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT01854918

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

Not yet reported Amgen 3681 participants Est. completion 2018-05-31 363 sites Stand-alone

Other conditions: Hyperlipidemia and Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT01879319

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Not yet reported Amgen 164 participants 27 sites Stand-alone

Other conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT01953328

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk

Not yet reported Amgen 409 participants Est. completion 2014-06 54 sites Stand-alone

Other conditions: Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
View official trial listing →
Completed NCT NCT01984424

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Not yet reported Amgen 511 participants Est. completion 2017-11-21 58 sites Stand-alone

Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT02189837

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

Not yet reported Amgen 89 participants Est. completion 2015-03-05 2 sites Stand-alone

Other conditions: Primary Hyperlipidemia and Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT02207634

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Not yet reported Amgen 1974 participants Est. completion 2016-11-11 416 sites Stand-alone

Other conditions: Dyslipidemia
View official trial listing →
Completed NCT NCT02275156

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Not yet reported Amgen 18 participants Est. completion 2014-12-19 1 site Stand-alone

Other conditions: Hyperlipidemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT02304484

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Not yet reported Amgen 770 participants Est. completion 2018-03-09 126 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT02392559

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Not yet reported Amgen 158 participants Est. completion 2019-11-25 66 sites Stand-alone

Other conditions: Heterozygous Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT02585895

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Not yet reported Amgen 39 participants Est. completion 2017-01-20 17 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT02624869

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Not yet reported Amgen 163 participants Est. completion 2021-06-01 46 sites Stand-alone

Other conditions: Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT02634580

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Not yet reported Amgen 61 participants Est. completion 2018-05-26 35 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT02662569

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

Not yet reported Amgen 986 participants Est. completion 2017-12-06 110 sites Stand-alone

Other conditions: Diabetes, Hyperlipidemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT02729025

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Not yet reported Amgen 129 participants Est. completion 2018-04-05 15 sites Stand-alone

Other conditions: Subjects With Hyperlipidemia, Dyslipidemia
View official trial listing →
Completed NCT NCT02739984

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

Not yet reported Amgen 424 participants Est. completion 2017-08-03 66 sites Stand-alone

Type 2 diabetes Other conditions: Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT02770131

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Amgen 1986 participants Est. completion 2021-06-30 183 sites

Other conditions: Hypercholesterolaemia
View official trial listing →
Completed NCT NCT02808403

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

Amgen 6000 participants Est. completion 2023-03-30 138 sites

Other conditions: Hypercholesterolemia, Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT02833844

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Not yet reported Amgen 467 participants Est. completion 2020-01-27 78 sites Stand-alone

Other conditions: Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
View official trial listing →
Completed NCT NCT02867813

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Not yet reported Amgen 5035 participants Est. completion 2022-03-21 198 sites Stand-alone

Other conditions: Dyslipidemia
View official trial listing →
Terminated NCT NCT02906124

Study to Evaluate the Safety of Repatha® in Pregnancy

Amgen 4 participants Est. completion 2020-11-06 48 sites

Other conditions: Hypercholesterolaemia, Pregnancy
View official trial listing →
Withdrawn NCT NCT02941016

Vascular Inflammation and Cholesterol Lowering Therapy

Not yet reported Rigshospitalet, Denmark Est. completion 2020-10-01 1 site Stand-alone

Other conditions: Lipid Lowering, Vascular Inflammation
View official trial listing →
Completed NCT NCT02948777

Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

Not yet reported Marja-Riitta Taskinen 14 participants Est. completion 2018-06 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Terminated NCT NCT02957604

Evolocumab Pregnancy Exposure Registry

Amgen 140 participants Est. completion 2020-09-02

Cardiovascular disease
View official trial listing →
Completed NCT NCT03060577

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Not yet reported Novartis Pharmaceuticals 382 participants Est. completion 2021-12-17 52 sites

Cardiovascular diseaseType 2 diabetes Other conditions: Symptomatic Atherosclerosis, Familial Hypercholesterolemia
View official trial listing →
Terminated NCT NCT03080935

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Not yet reported Amgen 1600 participants Est. completion 2022-03-04 85 sites Stand-alone

Other conditions: Dyslipidemia
View official trial listing →
Completed NCT NCT03096288

Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity

Not yet reported University of Florida 259 participants Est. completion 2020-11-02 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT03110432

Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

GWT-TUD GmbH 1695 participants Est. completion 2024-04-17 3 sites

Other conditions: Dyslipoproteinemias, Hypercholesterolemia, Familial, Familial Hypercholesterolemia - Homozygous, Familial Combined Hyperlipidemia
View official trial listing →
Completed NCT NCT03175367

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Not yet reported Regeneron Pharmaceuticals 272 participants Est. completion 2020-12-14 95 sites Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT03193047

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Not yet reported Esperion Therapeutics, Inc. 59 participants Est. completion 2018-02-19 1 site Stand-alone

Other conditions: Hypercholesterolemia
View official trial listing →
Terminated NCT NCT03247972

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

Inova Health Care Services 30 participants Est. completion 2019-10-01 1 site

Other conditions: Peripheral Arterial Disease
View official trial listing →
Terminated NCT NCT03258281

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

Not yet reported Inova Health Care Services 4 participants Est. completion 2019-10-01 1 site

Type 2 diabetes Other conditions: Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
View official trial listing →
Completed NCT NCT03287609

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Not yet reported Insel Gruppe AG, University Hospital Bern 308 participants Est. completion 2019-08-07 7 sites

Other conditions: Acute Coronary Syndrome
View official trial listing →
Terminated NCT NCT03331666

Impact of LDL-cholesterol Lowering on Platelet Activation

Not yet reported Columbia University 4 participants Est. completion 2020-02-04 1 site

Other conditions: Familial Hypercholesterolemia
View official trial listing →
Terminated NCT NCT03337698

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Not yet reported, Not yet reported Hoffmann-La Roche 314 participants Est. completion 2025-11-25 29 sites Stand-alone

Other conditions: Carcinoma, Non-Small-Cell Lung
View official trial listing →
Completed NCT NCT03403374

Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia

Not yet reported Amgen 30 participants Est. completion 2019-11-27 12 sites Stand-alone

Other conditions: Homozygous Familial Hypercholesterolemia HoFH
View official trial listing →
Completed NCT NCT03429998

Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia

Not yet reported Hospital General Universitario Gregorio Marañon 9 participants Est. completion 2018-01-28 1 site

Other conditions: Hypercholesterolemia
View official trial listing →
Terminated NCT NCT03433755

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Not yet reported Amgen 259 participants Est. completion 2020-05-09 31 sites Stand-alone

Other conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
View official trial listing →
Completed NCT NCT03500302

Effect of Evolocumab on Coronary Endothelial Function

Not yet reported Johns Hopkins University 19 participants Est. completion 2019-11-30 1 site Stand-alone

Cardiovascular disease Other conditions: Human Immunodeficiency Virus
View official trial listing →
Completed NCT NCT03515304

Evolocumab in Acute Coronary Syndrome

Not yet reported Johns Hopkins University 60 participants Est. completion 2025-03-25 1 site Stand-alone

Other conditions: Acute Coronary Syndrome
View official trial listing →
Completed NCT NCT03570697

Imaging of Coronary Plaques in Participants Treated With Evolocumab

Not yet reported Amgen 164 participants Est. completion 2021-01-21 33 sites Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT03626831

Effect of Evolocumab on Vascular Function

Not yet reported University of Erlangen-Nürnberg Medical School 105 participants Est. completion 2021-07-12 1 site

Cardiovascular disease
View official trial listing →
Completed NCT NCT03689946

Effect of Evolocumab on Coronary Atherosclerosis

Not yet reported Cedars-Sinai Medical Center 55 participants Est. completion 2023-05-30 1 site Stand-alone

Cardiovascular disease Other conditions: Hyperlipidemia
View official trial listing →
Completed NCT NCT03734211

Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

Not yet reported Lars Gullestad 130 participants Est. completion 2023-05-20 5 sites Stand-alone

Other conditions: Cardiac Allograft Vasculopathy
View official trial listing →
Completed NCT NCT03791593

EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot

Not yet reported Fundació Institut Germans Trias i Pujol 46 participants Est. completion 2022-07-20 3 sites Stand-alone

Heart failure
View official trial listing →
Status unknown NCT NCT03811223

Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia

Not yet reported UMC Utrecht 30 participants Est. completion 2021-03 Stand-alone

Other conditions: Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III
View official trial listing →
Completed NCT NCT03829046

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

Not yet reported Robert Rosenson 41 participants Est. completion 2021-11-15 2 sites

Type 2 diabetes Other conditions: Atherosclerotic Vascular Disease, Microvascular Dysfunction
View official trial listing →
Withdrawn NCT NCT03851263

Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion

Not yet reported ECRI bv Est. completion 2023-02-24 Stand-alone

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT03869073

Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)

Not yet reported University of British Columbia 36 participants Est. completion 2021-02-11 3 sites Stand-alone

Other conditions: Sepsis
View official trial listing →
Completed NCT NCT03872401

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Not yet reported Amgen 12301 participants Est. completion 2025-07-25 852 sites Stand-alone

Other conditions: Coronary Heart Disease (CHD)
View official trial listing →
Completed NCT NCT03900026

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

Not yet reported Unity Health Toronto 782 participants Est. completion 2025-01-30 22 sites Stand-alone

Other conditions: Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
View official trial listing →
Status unknown NCT NCT03931161

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)

Not yet reported Imperial College Healthcare NHS Trust 33 participants Est. completion 2024-05-06 1 site

Other conditions: Carotid Artery Stenosis
View official trial listing →
Completed NCT NCT03932721

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

Not yet reported University of Campinas, Brazil 110 participants Est. completion 2021-10-30 1 site

Type 2 diabetes Other conditions: Dyslipidemia Associated With Type II Diabetes Mellitus, Hypertension Arterial
View official trial listing →
Completed NCT NCT03944577

Impact of Evolocumab in Cardiac Transplant Patients With CAV

Not yet reported University of Nebraska 26 participants Est. completion 2023-03-28 1 site Stand-alone

Other conditions: Heart Transplant
View official trial listing →
Completed NCT NCT04034485

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Not yet reported LIB Therapeutics LLC 65 participants Est. completion 2023-01-30 12 sites

Other conditions: Homozygous Familial Hypercholesterolemia
View official trial listing →
Terminated NCT NCT04073134

The CHORAL Flow Study

Not yet reported Imperial College London 12 participants Est. completion 2022-05-27 1 site

Cardiovascular disease Other conditions: Atherosclerosis, Hyperlipidemias
View official trial listing →
Completed NCT NCT04082442

Evolocumab in Patients With Acute MI

Not yet reported Johns Hopkins University 100 participants Est. completion 2024-10-25 1 site Stand-alone

Other conditions: Acute Coronary Syndrome
View official trial listing →
Status unknown NCT NCT04087915

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)

Beijing Anzhen Hospital 1000 participants Est. completion 2021-12-31 1 site

Cardiovascular disease Other conditions: Dyslipidemia
View official trial listing →
Status unknown NCT NCT04100434

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

Not yet reported Tianjin Chest Hospital 500 participants Est. completion 2023-06-01 1 site Stand-alone

Other conditions: Acute Coronary Syndrome, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
View official trial listing →
Status unknown NCT NCT04101643

PCSK9 Inhibitor Treatment for Patients With SPG5

Not yet reported, Not yet reported First Affiliated Hospital of Fujian Medical University 30 participants Est. completion 2023-01-03 1 site Stand-alone

Other conditions: Hereditary Spastic Paraplegia Type 5
View official trial listing →
Terminated NCT NCT04128475

Observational Study of Cardiovascular Disease.

University of Sydney 1137 participants Est. completion 2021-04-26 3 sites

Cardiovascular disease Other conditions: Cardiovascular Morbidity, Coronary Heart Disease, Low-density-lipoprotein-type
View official trial listing →
Completed NCT NCT04141579

Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody

Not yet reported Radboud University Medical Center 150 participants Est. completion 2023-11-09 1 site Stand-alone

Cardiovascular disease Other conditions: Atherosclerosis of Coronary Artery
View official trial listing →
Completed NCT NCT04189484

Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors

Not yet reported Food and Drug Administration (FDA) 72 participants Est. completion 2021-04-07 1 site Stand-alone

Other conditions: Healthy Subjects, Pharmacokinetics, Pharmacodynamics
View official trial listing →
Withdrawn NCT NCT04303377

Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction

Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia Est. completion 2020-07-24 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT04306081

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

Not yet reported Leonardo Clavijo 86 participants Est. completion 2021-03-30 1 site Stand-alone

Other conditions: Peripheral Arterial Disease
View official trial listing →
Status unknown NCT NCT04306471

Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

Not yet reported Leonardo Clavijo 32 participants Est. completion 2022-02-04 1 site Stand-alone

Other conditions: Critical Limb Ischemia
View official trial listing →
Status unknown NCT NCT04313270

Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

Federico II University 25 participants Est. completion 2025-12-01 1 site

Other conditions: Hypercholesterolemia, Familial
View official trial listing →
Terminated NCT NCT04314167

Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion

Not yet reported University Hospital Tuebingen 9 participants Est. completion 2024-03-01 1 site Stand-alone

Other conditions: Hypercholesterolemia, Insulin Resistance, Insulin Secretion
View official trial listing →
Completed NCT NCT04319081

Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors

Jose Seijas Amigo 180 participants Est. completion 2023-01-13 12 sites

Other conditions: Cognitive Function, Hypercholesterolemia, Quality of Life
View official trial listing →
Status unknown NCT NCT04338165

Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography

Not yet reported University Hospital, Grenoble 66 participants Est. completion 2022-11 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT04369664

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Not yet reported NYU Langone Health 151 participants Est. completion 2023-10-19 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT04397653

Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients

Not yet reported Policlinico Casilino ASL RMB 50 participants Est. completion 2020-12-14 1 site Stand-alone

Chronic kidney disease Other conditions: Hypercholesterolemia
View official trial listing →
Status unknown NCT NCT04416425

Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

Zibo Central Hospital 200 participants Est. completion 2023-02-27 1 site

Other conditions: Atherosclerosis
View official trial listing →
Withdrawn NCT NCT04510844

Evolocumab In Advanced Chronic Kidney Disease Trial

Not yet reported NYU Langone Health Est. completion 2021-10-01 2 sites Stand-alone

Chronic kidney disease Other conditions: High Cholesterol
View official trial listing →
Status unknown NCT NCT04539223

A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy

Not yet reported Canadian Medical and Surgical Knowledge Translation Research Group 60 participants Est. completion 2022-05 3 sites

Other conditions: Carotid Artery Stenosis, Asymptomatic Carotid Artery Stenosis
View official trial listing →
Terminated NCT NCT04573777

Reducing Intracranial atheroSclErosis With Repatha

Not yet reported University of California, Los Angeles 10 participants Est. completion 2021-12-16 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT04608474

Lipid Management in Renal Transplant Recipients Using Evolocumab.

Not yet reported Brigham and Women's Hospital 81 participants Est. completion 2025-05-14 1 site Stand-alone

Other conditions: Hyperlipidemias
View official trial listing →
Status unknown NCT NCT04613167

Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment

Not yet reported University Medical Centre Ljubljana 70 participants Est. completion 2021-10-01 1 site Stand-alone

Other conditions: Acute Coronary Syndrome, Premature Coronary Heart Disease, Lipoproteinemia, Inflammation, Genetic Polymorphisms
View official trial listing →
Active, not recruiting NCT NCT04656028

Genetic Testing and Motivational Counseling for FH

Not yet reported National Medical Research Center for Therapy and Preventive Medicine 180 participants Est. completion 2025-03-30 1 site Stand-alone

Other conditions: Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2, Hypercholesterolemia, Familial, 3, Hypercholesterolemia, Familial, 4, Hypercholesterolemia, Familial, 4, Autosomal Recessive, Familial Hypercholesterolemia With Hyperlipemia, Hypercholesterolemia, Autosomal Dominant, Type B, Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Dominant, 3, Apolipoprotein B-100, Familial Defective, Genetic Testing, Motivational Interviewing, Therapeutic Adherence, Therapeutic Adherence and Compliance, Treatment Adherence, Medication Adherence, Treatment Adherence and Compliance, Patient Adherence, Compliance, Patient Compliance, Familial Hypercholesterolemia, Familial Hypercholesterolemia - Heterozygous, Adherence, Patient, Adherence, Medication, Adherence
View official trial listing →
Status unknown NCT NCT04659525

Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia

Not yet reported Policlinico Casilino ASL RMB 50 participants Est. completion 2021-12-30 1 site Stand-alone

Chronic kidney disease Other conditions: Hypercholesterolemia
View official trial listing →
Completed NCT NCT04665830

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

Not yet reported Hamid Al-Essa Organ Transplant Center 200 participants Est. completion 2020-05-01 1 site

Other conditions: Kideny Transplant Recipients With High Cardiovascular Risk Score
View official trial listing →
Completed NCT NCT04710368

Effect of Evolocumab on Coronary Plaque Characteristics

Not yet reported Annapoorna Kini 137 participants Est. completion 2023-11-06 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT04719221

Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

Not yet reported Korea University Anam Hospital 60 participants Est. completion 2024-12 1 site

Other conditions: Clinical Trial, Acute Coronary Syndrome
View official trial listing →
Status unknown NCT NCT04730973

CARotid plaqUe StabilizatiOn and Regression With Evolocumab.

Not yet reported Azienda Ospedaliera Ordine Mauriziano di Torino 130 participants Est. completion 2022-03-31 1 site

Other conditions: Carotid Artery Disease
View official trial listing →
Completed NCT NCT04790513

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Not yet reported LIB Therapeutics LLC 204 participants Est. completion 2022-12-31 3 sites

Cardiovascular disease Other conditions: Hypercholesterolemia
View official trial listing →
Active, not recruiting NCT NCT04862260

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Not yet reported CHU de Quebec-Universite Laval 3 participants Est. completion 2026-12-31 2 sites Stand-alone

Other conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic Cancer
View official trial listing →
Completed NCT NCT04937413

The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

Not yet reported Duke University 32 participants Est. completion 2023-10-12 1 site Stand-alone

Other conditions: Malignant Glioma, Glioblastoma
View official trial listing →
Completed NCT NCT04941105

Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19

Not yet reported Collegium Medicum w Bydgoszczy 60 participants Est. completion 2022-05-17 1 site Stand-alone

Other conditions: Sars-CoV-2 Infection
View official trial listing →
Active, not recruiting NCT NCT04951856

Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

Not yet reported Assistance Publique - Hôpitaux de Paris 2166 participants Est. completion 2028-05-22 1 site Stand-alone

Cardiovascular disease Other conditions: NSTEMI - Non-ST Segment Elevation MI
View official trial listing →
Completed NCT NCT04992065

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Not yet reported Novo Nordisk A/S 267 participants Est. completion 2022-06-20 44 sites

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT05043740

PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population

Not yet reported Second Xiangya Hospital of Central South University 1360 participants Est. completion 2023-10-01 Stand-alone

Other conditions: Acute Coronary Syndrome
View official trial listing →
Terminated NCT NCT05144529

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Not yet reported Eziafa Oduah, MD, PhD, MPH 19 participants Est. completion 2024-09-27 1 site Stand-alone

Other conditions: Lung Cancer Metastatic
View official trial listing →
Completed NCT NCT05184530

In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction

First Affiliated Hospital Xi'an Jiaotong University 7556 participants Est. completion 2021-12

Other conditions: Coronary Disease
View official trial listing →
Active, not recruiting NCT NCT05284747

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Not yet reported Amgen 6019 participants Est. completion 2027-05-29 120 sites Stand-alone

Cardiovascular disease Other conditions: Coronary Revascularization
View official trial listing →
Status unknown NCT NCT05418166

Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome

First Affiliated Hospital of Harbin Medical University 30 participants Est. completion 2022-09-01 1 site

Other conditions: Acute Coronary Syndrome
View official trial listing →
Active, not recruiting NCT NCT05537948

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients

Not yet reported National Medical Research Center for Therapy and Preventive Medicine 59 participants Est. completion 2025-01-31 1 site

Other conditions: Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder, Immunosuppression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Statins
View official trial listing →
Status unknown NCT NCT05579418

The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

Not yet reported Hamad Medical Corporation 350 participants Est. completion 2024-10-30

Other conditions: STEMI, Dyslipidemias
View official trial listing →
Status unknown NCT NCT05585151

High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study

Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 200 participants Est. completion 2024-10-01 1 site Stand-alone

Other conditions: Cerebral Atherosclerosis
View official trial listing →
Not yet recruiting NCT NCT05587621

Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)

Not yet reported Jena University Hospital 300 participants Est. completion 2026-12-31 10 sites

Cardiovascular disease Other conditions: LDL-cholesterol
View official trial listing →
Terminated NCT NCT05613426

Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

Not yet reported Henan Institute of Cardiovascular Epidemiology 119 participants Est. completion 2026-05-16 6 sites Stand-alone

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT05623995

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

Not yet reported Lin Zhao 200 participants Est. completion 2025-12-01 1 site Stand-alone

Other conditions: In-stent Restenosis, Major Adverse Cardiovascular Events
View official trial listing →
Status unknown NCT NCT05624658

Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS

Not yet reported Samara Regional Cardiology Dispensary 200 participants Est. completion 2024-05 1 site

Other conditions: Dyslipidemias
View official trial listing →
Completed NCT NCT05661552

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Not yet reported Yonsei University 108 participants Est. completion 2025-02-05 1 site Stand-alone

Other conditions: Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
View official trial listing →
Status unknown NCT NCT05697185

Safety and Efficacy of Evolocumab in Ischemic Stroke

Not yet reported Second Affiliated Hospital of Guangxi Medical University 200 participants Est. completion 2024-12-01 Stand-alone

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT05741086

Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)

Not yet reported The First Affiliated Hospital with Nanjing Medical University 80 participants Est. completion 2024-08-31 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT05802108

Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

Not yet reported Zibo Central Hospital 60 participants Est. completion 2024-06-30 1 site Stand-alone

Other conditions: Adverse Effect of Cardiovascular Medications (Diagnosis)
View official trial listing →
Completed NCT NCT05974345

In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

Novartis Pharmaceuticals 204691 participants Est. completion 2023-12-15 1 site

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT05976893

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Not yet reported Xiang Xie 620 participants Est. completion 2025-12-31 Stand-alone

Cardiovascular disease Other conditions: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Cancer
View official trial listing →
Completed NCT NCT05984953

Rosuvastatin and Evolocumab for Coronary Artery Disease

Icahn School of Medicine at Mount Sinai 195 participants Est. completion 2022-10-28 1 site

Cardiovascular disease
View official trial listing →
Not yet recruiting NCT NCT06081153

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

Not yet reported University of Pennsylvania 44 participants Est. completion 2029-02-28 1 site Stand-alone

Other conditions: Abdominal Aortic Aneurysm
View official trial listing →
Active, not recruiting NCT NCT06081803

Evolocumab in STEMI

Not yet reported Sejong General Hospital 166 participants Est. completion 2025-12-31 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT06134635

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Xuanwu Hospital, Beijing 80 participants Est. completion 2024-12-01

Cardiovascular disease
View official trial listing →
Status unknown NCT NCT06140095

Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism

Not yet reported Region Stockholm 8 participants Est. completion 2025-12 Stand-alone

Other conditions: Acute Metabolic Effects of Evolocumab and Atorvastatin
View official trial listing →
Completed NCT NCT06231459

Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia

Not yet reported Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado 20 participants Est. completion 2020-12-31 1 site Stand-alone

Other conditions: Hypercholesterolemia, Familial
View official trial listing →
Active, not recruiting NCT NCT06284564

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Not yet reported M.D. Anderson Cancer Center 10 participants Est. completion 2026-10-01 2 sites Stand-alone

Other conditions: Metastatic Renal Cell Carcinoma
View official trial listing →
Active, not recruiting NCT NCT06295679

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Amgen 7000 participants Est. completion 2028-12-19 90 sites

Cardiovascular disease Other conditions: Major Cardiovascular Event
View official trial listing →
Status unknown NCT NCT06364124

Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

Not yet reported Beijing Luhe Hospital 84 participants Est. completion 2025-06-01 1 site Stand-alone

Other conditions: STEMI
View official trial listing →
Status unknown NCT NCT06381947

Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients

Not yet reported University of Salerno 130 participants Est. completion 2025-06-30

Cardiovascular disease Other conditions: Dyslipidemias, Statin Adverse Reaction, Lipid Metabolism Disorders
View official trial listing →
Completed NCT NCT06696820

Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke

Not yet reported, Not yet reported Xiang Luo 429 participants Est. completion 2026-06-03 2 sites Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT06740552

Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

Shanghai Zhongshan Hospital 1862 participants Est. completion 2025-10-31 1 site

Cardiovascular disease
View official trial listing →
Not yet recruiting NCT NCT06791031

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)

Not yet reported West China Hospital 212 participants Est. completion 2028-06 Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT07023445

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

Novartis Pharmaceuticals 37688 participants Est. completion 2024-06-28 1 site

Cardiovascular disease Other conditions: Familial Hypercholesterolemia
View official trial listing →
Not yet recruiting NCT NCT07084259

Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

Not yet reported Hanyang University Seoul Hospital 352 participants Est. completion 2030-07 Stand-alone

Cardiovascular disease
View official trial listing →
Not yet recruiting NCT NCT07174375

PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy

Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 478 participants Est. completion 2027-12-15 12 sites Stand-alone

Cardiovascular disease
View official trial listing →
Not yet recruiting NCT NCT07286110

Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial

Not yet reported Fudan University 66 participants Est. completion 2026-12-30 1 site Stand-alone

Other conditions: Moyamoya Disease, Moyamoya Syndrome
View official trial listing →
Completed NCT NCT07295366

Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial

Not yet reported The Affiliated Hospital of Xuzhou Medical University 60 participants Est. completion 2026-05-01 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT07301372

Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke

Not yet reported The Affiliated Hospital of Xuzhou Medical University 132 participants Est. completion 2026-06-01 1 site Stand-alone

Cardiovascular disease
View official trial listing →
Completed NCT NCT07422285

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

Not yet reported Amgen 405 participants Est. completion 2026-07-24 4 sites Stand-alone

Other conditions: Healthy Participants, Pharmacokinetics
View official trial listing →
Not yet recruiting NCT NCT07468500

Real World Adherence of PCSK9 Targeted Therapy

Novartis Pharmaceuticals 3600 participants Est. completion 2026-07-30

Other conditions: Dyslipidemia, Hypercholesterolemia
View official trial listing →
Active, not recruiting NCT NCT07545226

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.

Not yet reported Amgen 405 participants Est. completion 2026-09-03 4 sites Stand-alone

Other conditions: Healthy Participants
View official trial listing →
Not yet recruiting NCT NCT07674524

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

Sun Yat-sen University 160 participants Est. completion 2029-12-31 1 site

Other conditions: Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia, ALK Gene Mutation, ALK-positive
View official trial listing →
Not yet recruiting NCT NCT07803679

A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

Not yet reported Amgen 308 participants Est. completion 2029-04-30 Stand-alone

Cardiovascular disease Other conditions: Hypercholesterolemia, Atheroma, Atherosclerotic Plaque
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07803679

Also known as: Evolocumab, REPATHA, AMG 145

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.